Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This clinical study evaluates the efficacy and safety of anlotinib in patients with
hepatocellular carcinoma who have progressed on lenvatinib treatment. It is a single arm,
open-label clinical trial conducted in China, and plan to recruit 28 patients. Primary
endpoint of the study is Progress Free Survival.